Monte Rosa
Monte Rosa Therapeutics develops molecular glue degrader (MGD) programs to target undruggable or inadequately drugged proteins. The company utilizes a platform combining artificial intelligence, structural biology, and proteomics to identify and degrade specific disease-causing proteins. Their pipeline focuses on creating precision medicines for patients with limited treatment options.
Biotechnology
Healthtech
Artificial Intelligence
Funding summary
- Total raised
- €80.4M
- Funding rounds
- 1
Investors in Monte Rosa
Investors on record for Monte Rosa. Click any investor to view their CAPLINK profile and funding criteria.
Fundraising for a startup like Monte Rosa?
Explore CAPLINK's investor database of thousands of active VCs and angels.
Browse investors